News
-
Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, In Patients With Epilepsy
12/3/2012
Upsher-Smith Laboratories, Inc., (Upsher-Smith) announced that Phase I data for USL261 (intranasal midazolam) in patients with epilepsy were presented at the American Epilepsy Society Annual Meeting in San Diego, CA.
-
Immunovative Announces Regulatory Clearance To Conduct A Phase II/III Clinical Trial In Advanced Metastatic Breast Cancer For AlloStim™
11/29/2012
Immunovative, Inc. ("IMUN" or the "Company") (OTCQB: IMUN) announces today that Immunovative Therapies, Ltd. ("ITL") has been granted regulatory clearance from Thailand authorities to advance its lead AlloStim™ immunotherapy product candidate to the Phase II/III clinical development stage in advanced metastatic breast cancer.
-
Accelovance Strengthens Executive Team With Chief Medical Officer
11/14/2012
Accelovance, an award-winning clinical services company, announced recently the addition of Stephan A. Bart Sr., MD as Chief Medical Officer for the organization.
-
Zafgen Announces Initiation Of Phase 2a Clinical Development With Beloranib In Obesity
11/6/2012
Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced that it has initiated Phase 2a clinical testing of beloranib.
-
INC Research Discusses Benefits Of Involving CROs Early In Planning At Partnerships In Clinical Trials 2012
11/5/2012
INC Research, LLC, a therapeutically focused global clinical research organization (CRO) with a Trusted Process for delivering reliable results, will discuss the importance of involving CROs early in the planning process at the Partnerships in Clinical Trials conference, November 6-9, 2012 at the CCH Congress Center in Hamburg, Germany.
-
Phase III Data Show Greater Compliance Across Demographic Groups With Agile Therapeutics' Contraceptive Patch Compared To An Oral Contraceptive
11/1/2012
Agile Therapeutics presented findings from a phase III pivotal trial of AG200-15, Agile's investigational once-weekly combination contraceptive patch containing ethinyl estradiol (EE) in combination with levonorgestrel (LNG).
-
Blood Test With Potential To Detect Stage One Cancer: Soricimed Biopharma Inc. Announces Initiation Of Cancer Diagnostic Study
10/23/2012
Soricimed Biopharma Inc., a private clinical stage company developing novel cancer therapeutics and diagnostics, announced that a pre-regulatory study of their blood test for early detection of cancer has commenced.
-
Bayer's Investigational Riociguat Meets Primary Endpoint In Phase III Study Of Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
10/23/2012
Bayer HealthCare today announced data from the Phase III CHEST-1 trial evaluating its investigational drug riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or with persistent or recurrent pulmonary hypertension (PH) after surgery.
-
Phase IIa Laquinimod Trial Results Show Positive Data For Potential Use In Active Crohn's Disease
10/22/2012
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced the presentation of Phase IIa clinical data for investigational laquinimod in moderate to severe Crohn's disease (CD).
-
Clinical Research Advantage Earns Finalist Status In 8th Annual Stevie Awards For Women In Business
10/17/2012
Clinical Research Advantage, Inc. (CRA), a provider of a range of research services to pharmaceutical companies and contract research organizations (CROs), announced recently that its senior vice president of clinical operations, Kim Kundert, RN, BSN, CCRC, was named a finalist in one of the Best Executive (service businesses) categories in the 8th annual Stevie Awards for Women in Business.